Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Review

Hepatic arterial embolization in patients with neuroendocrine tumors

Authors: Michela Del Prete, Francesco Fiore, Roberta Modica, Vincenzo Marotta, Francesca Marciello, Valeria Ramundo, Antonella Di Sarno, Annachiara Carratù, Chiara de Luca di Roseto, Salvatore Tafuto, Fabiana Tatangelo, Robero Baldelli, Annamaria Colao, Antongiulio Faggiano, on the behalf of the Multidisciplinary Group for NeuroEndocrine Tumors of Naples

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient’s quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques.
TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases.
Literature
1.
Bosman FT: World Health Organization, and International Agency for Research on Cancer. WHO classification of tumours of the digestive system, World Health Organization classification of tumours. 2010, Lyon: International Agency for Research on Cancer, 417-4
2.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26 (18): 3063-3072. 10.1200/JCO.2007.15.4377.CrossRefPubMed
3.
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD, Knowledge NETwork: Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Canc. 2013, 21 (3): R153-R163.CrossRef
4.
Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA: Neuroendocrine hepatic metastases: does aggressive management improve survival?. Ann Surg. 2005, 241 (5): 776-783. 10.1097/01.sla.0000161981.58631.ab. discussion 783-5PubMedCentralCrossRefPubMed
5.
Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001, 92 (8): 2204-2210. 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R.CrossRefPubMed
6.
Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97 (4): 934-959. 10.1002/cncr.11105.CrossRefPubMed
7.
Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005, 19 (5): 753-781. 10.1016/j.bpg.2005.06.002.CrossRefPubMed
8.
Norheim I, Oberg K, Theodorsson-Norheim E, Lindgren PG, Lundqvist G, Magnusson A, Wide L, Wilander E: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987, 206 (2): 115-125. 10.1097/00000658-198708000-00001.PubMedCentralCrossRefPubMed
9.
Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S: Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003, 180 (5): 1379-1384. 10.2214/ajr.180.5.1801379.CrossRefPubMed
10.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference participants: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012, 95 (2): 157-176. 10.1159/000335597.CrossRefPubMed
11.
Blonski WC, Reddy KR, Shaked A, Siegelman E, Metz DC: Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World J Gastroenterol. 2005, 11 (48): 7676-7683.PubMed
12.
Oberg K, Norheim I, Lundqvist G, Wide L: Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin–alone or in combination with 5-FU. Acta Oncol. 1987, 26 (6): 429-432. 10.3109/02841868709113712.CrossRefPubMed
13.
Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001, 12 (Suppl 2): S111-S114. 10.1093/annonc/12.suppl_2.S111.CrossRefPubMed
14.
Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996, 38 (3): 430-438. 10.1136/gut.38.3.430.PubMedCentralCrossRefPubMed
15.
Strosberg JR, Nasir A, Hodul P, Kvols L: Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Canc Res. 2008, 2 (3): 113-125.
16.
Kulke MH: Gastrointestinal neuroendocrine tumors: a role for targeted therapies?. Endocr Relat Canc. 2007, 14 (2): 207-219. 10.1677/ERC-06-0061.CrossRef
17.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364 (6): 501-513. 10.1056/NEJMoa1003825.CrossRefPubMed
18.
Allison DJ, Modlin IM, Jenkins WJ: Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet. 1977, 2 (8052–8053): 1323-1325.CrossRefPubMed
19.
Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med. 1988, 108 (3): 340-344. 10.7326/0003-4819-108-3-340.CrossRefPubMed
20.
Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC: Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006, 17 (8): 1235-1249. 10.1097/01.RVI.0000232177.57950.71. quiz 1250CrossRefPubMed
21.
Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA: Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003, 9 (4): 261-267. 10.1097/00130404-200307000-00008.CrossRefPubMed
22.
Pelage JP, Soyer P, Boudiaf M, Brocheriou-Spelle I, Dufresne AC, Coumbaras J, Rymer R: Carcinoid tumors of the abdomen: CT features. Abdom Imaging. 1999, 24 (3): 240-245. 10.1007/s002619900488.CrossRefPubMed
23.
Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A: Limitations of Chromogranin A in clinical practice. Biomarkers. 2012, 17 (2): 186-191. 10.3109/1354750X.2012.654511.CrossRefPubMed
24.
Oberg K, Stridsberg M: Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol. 2000, 482: 329-337.CrossRefPubMed
25.
Carling RS, Degg TJ, Allen KR, Bax ND, Barth JH: Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem. 2002, 39 (Pt 6): 577-582.CrossRefPubMed
26.
Lamberts SW, Hofland LJ, Nobels FR: Neuroendocrine tumor markers. Front Neuroendocrinol. 2001, 22 (4): 309-339. 10.1006/frne.2001.0218.CrossRefPubMed
27.
Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, Del Basso De Caro ML, Milone F, Scarpelli G, Masone S, Santeusanio F, Lombardi G, Angeletti G, Colao A: The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008, 31 (3): 277-286. 10.1007/BF03345602.CrossRefPubMed
28.
Panzuto F, Falconi M, Nasoni S, Angeletti S, Moretti A, Bezzi M, Gualdi G, Polettini E, Sciuto R, Festa A, Scopinaro F, Corleto VD, Bordi C, Pederzoli P, Delle Fave G: Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Ann Oncol. 2003, 14 (4): 586-591. 10.1093/annonc/mdg160.CrossRefPubMed
29.
Seemann MD: Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18 F-TOCA PET, triple-phase CT, and PET/CT. Technol Canc Res Treat. 2007, 6 (3): 213-220.CrossRef
30.
Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E: Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005, 23 (1): 70-78. 10.1200/JCO.2005.01.013.CrossRefPubMed
31.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000, 27 (3): 273-282. 10.1007/s002590050034.CrossRefPubMed
32.
Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D: Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res. 2007, 27 (6B): 4087-4094.PubMed
33.
Lopci E, Nanni C, Rampin L, Rubello D, Fanti S: Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours. Minerva Endocrinol. 2008, 33 (3): 277-281.PubMed
34.
Nicholson SA, Ryan MR: A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation. Cancer. 2000, 90 (3): 148-161. 10.1002/1097-0142(20000625)90:3<148::AID-CNCR3>3.0.CO;2-9.CrossRefPubMed
35.
Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S: The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986, 147 (1): 149-154. 10.2214/ajr.147.1.149.CrossRefPubMed
36.
Venook AP: Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol. 1999, 11 (1): 38-41. 10.1097/00001622-199901000-00009.CrossRefPubMed
37.
Strosberg JR, Cheema A, Kvols LK: A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control. 2011, 18 (2): 127-137.PubMed
38.
Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S, Joehl RJ: Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001, 130 (4): 677-682. 10.1067/msy.2001.117377. discussion 682-5CrossRefPubMed
39.
Strosberg JR, Choi J, Cantor AB, Kvols LK: Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006, 13 (1): 72-78.PubMed
40.
Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005, 104 (8): 1590-1602. 10.1002/cncr.21389.CrossRefPubMed
41.
Schell SR, Camp ER, Caridi JG, Hawkins IF: Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg. 2002, 6 (5): 664-670. 10.1016/S1091-255X(02)00044-6.CrossRefPubMed
42.
Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjø J, Dolva LO: Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol. 1989, 24 (7): 787-795. 10.3109/00365528909089215.CrossRefPubMed
43.
Wangberg B, Westberg G, Tylén U, Tisell L, Jansson S, Nilsson O, Johansson V, Scherstén T, Ahlman H: Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg. 1996, 20 (7): 892-899. 10.1007/s002689900136. discussion 899CrossRefPubMed
44.
Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE: Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998, 83 (11): 2293-2301. 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E.CrossRefPubMed
45.
Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH: Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999, 10 (4): 397-403. 10.1016/S1051-0443(99)70055-2.CrossRefPubMed
46.
Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000, 190 (4): 432-445. 10.1016/S1072-7515(00)00222-2.CrossRefPubMed
47.
Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO: Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007, 18 (7): 847-855. 10.1016/j.jvir.2007.04.018.CrossRefPubMed
48.
Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB: Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007, 188 (5): 1201-1207. 10.2214/AJR.06.0933.CrossRefPubMed
49.
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME: Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol. 2008, 31 (2): 299-307. 10.1007/s00270-007-9186-3.CrossRefPubMed
50.
Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA: Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg. 2008, 12 (11): 1951-1960. 10.1007/s11605-008-0640-6.PubMedCentralCrossRefPubMed
51.
Sward C, Johanson V, Nieveen van Dijkum E, Jansson S, Nilsson O, Wängberg B, Ahlman H, Kölby L: Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg. 2009, 96 (5): 517-521. 10.1002/bjs.6587.CrossRefPubMed
52.
Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A: Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014, [Epub ahead of print]
53.
Perez EA, Koniaris LG, Snell SE, Gutierrez JC, Sumner WE, Lee DJ, Hodgson NC, Livingstone AS, Franceschi D: 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg. 2007, 31 (5): 1022-1030. 10.1007/s00268-005-0774-6.CrossRefPubMed
54.
Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P, Ruszniewski P: Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000, 12 (2): 151-157. 10.1097/00042737-200012020-00004.CrossRefPubMed
55.
Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D: Treatment of metastatic glucagonoma to the liver: case report and literature review. Ital J Gastroenterol Hepatol. 1999, 31 (4): 308-312.PubMed
56.
Lee SM, Forbes A, Williams R: Metastatic islet cell tumour with clinical manifestations of insulin and glucagon excess: successful treatment by hepatic artery embolization and chemotherapy. Eur J Surg Oncol. 1988, 14 (3): 265-268.PubMed
57.
Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993, 71 (8): 2624-2630. 10.1002/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B.CrossRefPubMed
Metadata
Title
Hepatic arterial embolization in patients with neuroendocrine tumors
Authors
Michela Del Prete
Francesco Fiore
Roberta Modica
Vincenzo Marotta
Francesca Marciello
Valeria Ramundo
Antonella Di Sarno
Annachiara Carratù
Chiara de Luca di Roseto
Salvatore Tafuto
Fabiana Tatangelo
Robero Baldelli
Annamaria Colao
Antongiulio Faggiano
on the behalf of the Multidisciplinary Group for NeuroEndocrine Tumors of Naples
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-33-43

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion

Research

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial

Research

Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

Research

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

Research

Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study

Research

Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits